The US Food and Drug Administration has accepted a biologics license application from Shanghai Henlius Biotech for its trastuzumab biosimilar candidate, codenamed HLX02.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?